<DOC>
	<DOCNO>NCT02190747</DOCNO>
	<brief_summary>Fibrodysplasia ossificans progressiva ( FOP ) rare , severely disable disease characterize painful , recurrent episode soft tissue swell ( flare-up ) result abnormal bone formation muscle , tendon , ligament . Flare-ups begin early life may occur spontaneously soft tissue trauma , vaccination , influenza infection . Recurrent flare-ups progressively restrict movement lock joint lead cumulative loss function disability . Mouse model FOP demonstrate ability retinoic acid receptor ( RAR ) gamma agonist prevent heterotopic ossification ( HO ) follow injury . The purpose study evaluate whether palovarotene , RAR gamma agonist , prevent HO follow flare-up subject FOP .</brief_summary>
	<brief_title>An Efficacy Safety Study Palovarotene Treat Preosseous Flare-ups FOP Subjects</brief_title>
	<detailed_description>The primary objective evaluate ability different dos palovarotene prevent HO flare-up site subject FOP assess plain radiograph . This Phase 2 , multi-center , randomize , double-blind , sponsor-unblinded , placebo-controlled study . Two cohort subject randomize different dose regimen palovarotene 6-week ( 42 day ) treatment period . The study consist three period : 1 . A Screening period occur within 7 day distinct flare-up . The first dose study drug take within 7 day flare-up initiation . 2 . A double-blind treatment period 6 week ( 42 day ) duration . 3 . A follow-up period 6 week ( 42 day ) duration . An initial cohort ( Cohort 1 ) subject randomly assign 3:1 either palovarotene placebo daily 42 day . Subjects randomize palovarotene Cohort 1 receive initial daily dose 10 mg 14 day follow 5 mg daily 28 day . In Cohort 2 , new FOP subject meet inclusion/exclusion criterion randomly assign 3:3:2 two dose regimen palovarotene ( 10 mg 14 day 5 mg 28 day ; 5 mg 14 day 2.5 mg 28 day ) placebo daily 42 day . Doses weight-adjusted subject randomize within three weight-range category ( 20 &lt; 40 kg , 40 &lt; 60 kg , â‰¥60 kg ) . Subjects complete study still meet eligibility requirement give opportunity enroll open-label extension study .</detailed_description>
	<mesh_term>Myositis Ossificans</mesh_term>
	<criteria>Written , sign , date informed subject/parent consent ageappropriate assent . Subjects clinically diagnose classic Fibrodysplasia Ossificans Progressiva ( FOP ) . Symptomatic onset distinct flareup within 7 day Study Day 1 ( start study drug ) define presence least two six follow symptom : pain , soft tissue swell , decrease range motion , stiffness , redness , warmth . Flareup must confirm physician Screening visit . Flareup appendicular area ( upper low extremity ) , abdomen , chest ; subject receive , receive , willing receive treatment per standard care , may may include oral prednisone ( 2 mg/kg PO maximum dose 100 mg daily ) 4 day . Abstinent use two highly effective form birth control . Subjects must accessible treatment followup . Subjects live distant location investigational site must able willing travel site initial followup visit . Weight &lt; 20 kg . Intercurrent nonhealed fracture location . Complete immobilization joint site flareup . The inability subject undergo imaging assessment use plain radiograph . If currently use vitamin A beta carotene , multivitamins contain vitamin A beta carotene , herbal preparation , fish oil , unable unwilling discontinue use product duration study . Exposure synthetic oral retinoids past 30 day prior Screening ( signature inform consent ) . Concurrent treatment tetracycline due potential increase risk pseudotumor cerebri . History allergy hypersensitivity retinoids lactose . Concomitant medication inhibitor inducer CYP450 3A4 activity . Amylase lipase &gt; 1.5x upper limit normal history chronic pancreatitis . Elevated aspartate aminotransferase alanine aminotransferase &gt; 2.5x upper limit normal . Fasting triglyceride &gt; 400 mg/dL without therapy .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Intervention study</keyword>
	<keyword>Clinical trial Phase 2</keyword>
	<keyword>Efficacy safety</keyword>
	<keyword>Heterotopic ossification</keyword>
	<keyword>Flare-up</keyword>
	<keyword>Palovarotene</keyword>
	<keyword>Retinoic acid receptor agonist</keyword>
	<keyword>Retinoic acid receptor gamma agonist</keyword>
	<keyword>Clementia</keyword>
	<keyword>Myositis Ossificans Progressiva</keyword>
	<keyword>Munchmeyer 's Disease</keyword>
	<keyword>FOP</keyword>
</DOC>